Elanco Animal Health (NYSE:ELAN) Issues Q1 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its first quarter 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.290-0.340 for the period, compared to the consensus estimate of 0.300. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.800-0.860 EPS.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ELAN shares. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. UBS Group began coverage on Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 target price on the stock. Leerink Partners initiated coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price on the stock. Barclays upped their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Finally, Stifel Nicolaus cut their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Hold” and a consensus price target of $16.00.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN traded down $0.56 during mid-day trading on Tuesday, reaching $10.55. 1,252,305 shares of the company traded hands, compared to its average volume of 4,574,833. The company’s 50 day moving average price is $11.78 and its 200-day moving average price is $13.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm has a market cap of $5.21 billion, a PE ratio of 26.34, a PEG ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a 52 week low of $10.20 and a 52 week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the firm posted $0.08 earnings per share. The business’s revenue was down 1.4% on a year-over-year basis. On average, equities analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.